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Abstract
Sleeping sickness disease (human African trypanosomiasis) is still a major health threat 
to a large number of people in 36 countries of sub-Saharan Africa. Currently, the 
estimated infection cases in these areas are between 300,000 and 500,000. Trypanosoma 
brucei gambiense and Trypanosoma brucei rhodesiense are the pathogens of sleeping 
sickness in humans. These parasites live and proliferate mainly in the blood and tissue 
fluids of the infected mammals and are transmitted by tsetse flies (Glossina spp.). The 
disease starts from a bite by an infected tsetse fly and goes through an initial stage, 
where trypanosomes multiply in the bloodstream and the lymphatic system. The disease 
will progress quickly without effective treatment, and the trypanosomes will cross the 
blood-brain barrier and invade the central nervous system eventually. In the late stage, 
patients will show a variety of neurological symptoms and often exhibit characteristic 
signs such as an alteration of the circadian sleep/wake pattern, which is how the disease 
is named “sleeping sickness”. The disease will result in wasting of body tissue, coma, 
and ultimate death. There is an urgent need to develop better chemotherapeutic agents 
for the treatment of trypanosomiasis. Exploring the new application of existing 
medicines is a new trend in drug development field. There are multiple advantages of 
this strategy. First, the manufactory of these agents is mature already. Second, the 
toxicity profiles of the existing medicines are well established, which can be used to 
guide the new clinical testing if their anti-trypanosomiasis activity is identified. Third, 
multiple administration routes of the medicines are well-developed which may include 
the oral administration formulation. Oral administration route is very critical for the 
treatment due to the limited medical resource at sub-Saharan Africa area. Our group has 
developed and validated an easy operating high throughput screening (HTS) cell 
proliferation assay with T. brucei cells, and two mammalian cell lines. Sigma-Aldrich 
provides a LOPAC compound library (about 1300 chemicals), which consist of all the 
current clinical medicines and drug candidates in clinical trials, which are used for the 
high throughput screening process. The results from the screening are summarized.
